Grant from Defense Threat Reduction Agency includes purchase of Pattern’s ProSpectral research platform
REDMOND, WA, November 15, 2023 — Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Lawrence Berkeley National Laboratory (LBNL) and Los Alamos National Laboratory (LANL) will be using the Pattern ProSpectral™ research platform to advance their innate-immunity based agnostic diagnostics program. Under the leadership of Harshini Mukundan, Ph.D., program manager for chemical and biological technologies within the Office of National and Homeland Security at LBNL, the project aims to decode the complexity of innate immune responses to develop universal pathogen-agnostic diagnostics.
The Company invented the first Pattern Discovery Engine™ (PDE™) for identifying novel patterns in complex data that cannot be discovered using conventional analytical techniques, algorithms, or tools. Pattern used the PDE to create the ProSpectral platform to be used in this study.
The Company noted that Pattern is a participating member of a new research grant, “Multi-wavelength Spectroscopy as a non-invasive, pathogen agnostic diagnostic for identification of emerging infectious diseases,” provided by the Defense Threat Reduction Agency (DTRA). The grant includes a provision for the purchase of Pattern’s ProSpectral medical diagnostic platform.
ProSpectral is a portable system capable of continuous collection of spectral signatures in clinical samples such as saliva. The instrument may incorporate pattern recognition via embedded AI/ML algorithms and can decode the same within seconds at the point of need, without the need for any additional reagents or supplies. ProSpectral will be used in the research study to measure the spectral signatures of target analytes in saliva. The signatures will be analyzed by researchers using tools including the Pattern Discovery Engine, which will provide explainable feedback regarding the behavior of the analytes of interest for disease diagnosis.
Dr. Mukundan commented, “This collaboration with Pattern builds on previous proof-of-concept work with Jessica Kubicek-Sutherland, Ph.D., LANL Staff Scientist, Physical Chemistry and Applied Spectroscopy Chemistry Division, who performed the initial clinical validation studies on the ProSpectral instrument. Pattern’s algorithms and ProSpectral were used successfully to identify metabolites in saliva from COVID patients with 99% corroboration with disease status, as affirmed by PCR. The spectral read out time is 3 seconds per measurement.” Mukundan has been leading the development of pathogen-agnostic diagnostics that mimic innate immunity, first from LANL and more recently at LBNL, for almost two decades. Previous work from her team – including the Intelligent Immunity program – is focused on unraveling complex interaction patterns associated with innate immune mechanisms. The success of the aforementioned COVID-19 study led her to propose the use of this platform to measure innate immune biomarkers in saliva using hyperspectral imaging.
Mark R. Anderson, Pattern Chair and CEO, commented, “Emerging infectious diseases are a major concern in national health security. Pattern is honored to support the Intelligent Immunity project, utilizing the ProSpectral device to continue driving forward this innovative and far-reaching research intended to enable front-line workers to distinguish between viral, bacterial, fungal, or parasitic infections in seconds, in the field.”
About ProSpectral™
Pattern has created a line of light-based devices which can detect the presence of diseases in three seconds. Using 100ml (two drops) of saliva placed into a small disposable sample container, a broad-spectrum light source is passed through the saliva and the light absorption pattern is captured by the device. The device, utilizing an accurate model of Covid-19’s absorption pattern, identifies an active Covid-19 infection with 98.8% balanced accuracy in the proof of concept. In critical environments where no individual shall pass with Covid-19, the accuracy of the device can be adjusted to 100% detection with up to 8% false positives. The ProSpectral prototype can process a sample in 10 seconds including the time to place and remove the sample container. This allows for a throughput of 360 tests per hour at a cost per test significantly lower than current technologies. The throughput may be increased to 1,200 tests per hour with the addition of high throughput accessory attachments under development. No reagents are required. The accuracy of each test is nearly equivalent to the current gold standard of a nasopharyngeal sample processed through an RT-PCR device. ProSpectral is ideally suited for situations where many people need to be tested in a short amount of time and/or on a frequent basis. The non-invasive sample collection eliminates patient discomfort, simplifies the testing process, and will likely increase voluntary compliance with regards to testing. The device is designed to meet FDA 21 CFR 820 and internationally ISO 13485.2016 guidelines. Regulatory approvals will be sought before availability in each market.
About Defense Threat Reduction Agency
The Defense Threat Reduction Agency provides cross-cutting solutions to enable the Department of Defense, the United States Government, and international partners to deter strategic attack against the United States and its allies; prevent, reduce, and counter weapons of mass destruction (WMD) and emerging threats; and prevail against WMD-armed adversaries in crisis and conflict.
About Pattern
Pattern Computer, Inc., a Seattle-area company, uses its proprietary Pattern Discovery Engine™ to solve the most important and intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major Pattern Discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. www.patterncomputer.com.
CONTACT: Laura Guerrant-Oiye 808-960-2642 – laura@patterncomputer.com
The foregoing contains statements about Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright © 2023 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.